Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian biotechnology company Sanomune has licensed a new treatment method that reportedly helps drugs to reach the brain unlike any other treatment for neurological diseases.
Subscribe to our email newsletter
The intranasal method was developed by William Frey II, senior director of HealthPartners Research Foundation’s Alzheimer’s Research Center, and his colleagues.
According to Sanomune, the new method allows medication to bypass the protective blood-brain barrier and enter the brain directly. Dr Frey developed a way to bypass the barrier for neurological conditions using intranasal delivery of deferoximine or SAN-121.
Dr Frey said: “With our non-invasive delivery method, the drug bypasses the blood-brain barrier and is rapidly delivered to the brain while significantly reducing unwanted side effects. Because it is able to reach key areas involved in both Alzheimer’s disease and Parkinson’s disease, we are very optimistic about its potential as a treatment for these disorders.”